When was Biocytogen founded?

Biocytogen was founded in 2008 and raised its 1st funding round 5 years after it was founded.

Where is Biocytogen located?

Biocytogen is headquartered in Wakefield, United States. It is registered at Wakefield, Massachusetts.

Who is the current CEO of Biocytogen?

Yuelei Shen of Biocytogen. They have also founded 1 company.

How many employees does Biocytogen have?

As of Aug 31, 2026, the latest employee count at Biocytogen is 229.

Is Biocytogen a funded company?

Biocytogen is a funded company, having raised a total of $301M across 7 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 19, 2013.

When was the latest funding round of Biocytogen?

Biocytogen's latest funding was a $***** Series D round on Jun 22, 2021, with participation from 3 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $2.25B in funding in 2026 to date.

Where does Biocytogen rank among its competitors?

Biocytogen ranks 1st amongst 96 active competitors, of which 14 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Sus Clinicals, which secured $2M in Aug, 2025.

Who are the top competitors of Biocytogen?

Biocytogen's top competitors include Applied StemCell, GemPharmatech and GenOway. Among them, Sus Clinicals secured the most recent funding round in August, 2025.

Biocytogen - 2026 Company Profile, Team, Funding & Competitors

Biocytogen is a public company based in Wakefield (United States), founded in 2008 by Yuelei Shen. It operates as a Provider of integrated solutions for next-generation antibody drug development. Biocytogen has raised $301M in funding from investors like CMB International Capital, SDIC and BioVeda China Fund. The company has 96 active competitors, including 14 funded and 13 that have exited. Its top competitors include companies like Applied StemCell, GemPharmatech and GenOway.

Company Details

Provider of integrated solutions for next-generation antibody drug development. The company offers a seamlessly integrated platform for antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMab mice), and in vivo or in vitro preclinical validation studies.

Website: biocytogen.com
Social
Email ID: *****@biocytogen.com
Phone Number: +1 **********
Registered Address: Wakefield, Massachusetts

Key Metrics

Founded Year

2008

Location

Wakefield, United States

Stage

Public

Total Funding

$301M in 7 rounds

Latest Funding Round

Series D, Jun 22, 2021, $*****

Investors

CMB International Capital & 12 more

Ranked

1^st among 96 active competitors

Employee Count

229 as on Aug 31, 2026

Similar Companies

Applied StemCell & 106 more

Exit Details

Public

View Biocytogen's full profile

Biocytogen is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
BIOCYTOGEN BOSTON CORP CIN: 001t000000hJgQ5AAK , United States, Deadpooled		-	-	-
BIOCYTOGEN BOSTON CORP. CIN: 830924428 , United States, Active	Dec 31, 1999	-	90 (As on Dec 31, 2024)	-
BIOCYTOGEN, LLC CIN: 262850678 , United States, Active	Jun 22, 2008	-	20 (As on Dec 31, 2018)	-

Biocytogen got listed on Sep 01, 2022.

Click here to take a look at Biocytogen's IPO in detail

Biocytogen has raised a total funding of $301M over 7 rounds. Its first funding round was on Aug 19, 2013. Its latest funding round was a Series D round on Jun 22, 2021 for $*****. 3 investors participated in its latest round. Biocytogen has 13 institutional investors.

Here is the list of recent funding rounds of Biocytogen:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 22, 2021	2739126	Series D	5109577	2292141	5454480	8845113
Sep 15, 2020	4599044	Series D	9836294	2195679	9906020	6470406
Aug 09, 2019	8924337	Series D	1884000	2714280	SDIC Venture Capital Management & 1 more	3E Bioventures Capital & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Biocytogen's funding rounds and investors

The founders of Biocytogen is Yuelei Shen. Yuelei Shen is the CEO of Biocytogen.

Here are the details of Biocytogen's key team members:

Yuelei Shen: Founder & CEO of Biocytogen.
Contact Info: 1 email address

View details of Biocytogen's Founder profiles and Board Members

Biocytogen's employee count trend

Biocytogen has 229 employees as of Aug 26. Here is Biocytogen's employee count trend over the years:

Uncover Biocytogen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Biocytogen include Applied StemCell, GemPharmatech and GenOway. Here is the list of Top 10 competitors of Biocytogen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Biocytogen 2008, Wakefield (United States), Public	Provider of integrated solutions for next-generation antibody drug development	$301M	China Life Insurance, Lake Bleu Capital & 11 others	67/100
2nd	Applied StemCell 2008, Milpitas (United States), Acquired	Provider of animal and cell line models as tools for drug discovery and diagnostics	$67.5M	Fosun, Advantech Capital & 8 others	59/100
3rd	GemPharmatech 2018, Nanjing (China), Public	Provider of humanized models and drug screening technologies	$81.9M	Sequoia Capital China, Hillhouse & 6 others	59/100
4th	GenOway 1999, Lyon (France), Public	Provider of transgenic rodent models and customized cell lines for preclinical development	$11.6M	Eurostars, Dassault Developpement & 7 others	58/100
5th	Hera Biolabs 2015, Lexington (United States), Acquired	Provider of rodent models for in vitro and in vivo safety and efficacy testing services	$3.39M	Enterprise Angels Community Fund I, Bluegrass Angels ... & 1 others	52/100
6th	Taconic 1952, Hudson (United States), Acquired	Provider of animal models and laboratory services	-	HIG BioHealth Partners, Falcon Investment Advisors	51/100
7th	InVivo Biosystems 2019, Eugene (United States), Series A	Provider of animal models for in-vivo analytical services	$8.16M	Rogue Venture Partners, Launch Oregon & 6 others	46/100
8th	Business Catalyst 2004, San Jose (United States), Series A	-	$1.25M	Midven	46/100
9th	Sus Clinicals 2020, Cincinnati (United States), Series A	Provider of preclinical testing services using pig models	$3.7M	HHS	43/100
10th	Kimera Labs 2012, Miramar (United States), Unfunded	Developer of perinatal exosome products for research and therapeutic purposes	-	-	42/100